ASPSCR1
ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.
Overview
Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface. Enhances VCP methylation catalysed by VCPKMT.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.79, genetic association 0.09, somatic mutation 0.96). In OnCo, 1 product record names it (Cediranib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.
- 1 · What it is
ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.
- 2 · What goes wrong in cancer
Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface.
- 3 · How drugs use it
No product in this corpus aims at ASPSCR1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:13825 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BZE9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000169696 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: sarcoma 0.56 (GraphQL API, CC0))
Biology
Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface. Enhances VCP methylation catalysed by VCPKMT. Location: Endomembrane system; Endoplasmic reticulum-Golgi intermediate compartment membrane; Cytoplasm; Nucleus (UniProt). Locus 17q25.3 (HGNC).
- Sarcomas: Open Targets association 0.56 with sarcoma (MONDO_0005089)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 1 OnCo product record names it; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ASPSCR1" OR ABSTRACT:"ASPSCR1" OR TITLE:"ASPSCR1 tether for SLC2A4, UBX domain containing" OR ABSTRACT:"ASPSCR1 tether for SLC2A4, UBX domain containing" OR TITLE:"Tether containing UBX domain for GLUT4" OR ABSTRACT:"Tether containing UBX domain for GLUT4" OR TITLE:"UBXD9" OR ABSTRACT:"UBXD9" OR TITLE:"UBXN9" OR ABSTRACT:"UBXN9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ASPSCR1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTFE3
Shares Cediranib, Sarcomas (soft tissue, bone, GIST), Open Targets Platform.
- CancerAlveolar soft part sarcoma
- TreatmentAnlotinib
- TreatmentPazopanib